41542-06-7

Usage

Uses

Used in Chemical Synthesis:
1-(2,3-Dichlorophenyl)-2-thiourea is used as a reagent in organic synthesis for its ability to facilitate various chemical reactions, contributing to the production of a wide array of chemical compounds.
Used in Pesticide Formulation:
In the agricultural industry, 1-(2,3-Dichlorophenyl)-2-thiourea is used as a herbicide for its effectiveness in controlling the growth of weeds. Its application helps to protect crops and improve agricultural yields by reducing competition from unwanted plant species.
Used as a Precursor in Chemical Production:
DCPPT serves as a precursor in the preparation of other chemical compounds, indicating its utility in the synthesis of more complex molecules for various applications across different industries.

InChI:InChI=1/C7H6Cl2N2S/c8-4-2-1-3-5(6(4)9)11-7(10)12/h1-3H,(H3,10,11,12)

Upstream product

• 608-27-5 2,3-dichloroaniline 
• 83697-81-8 N-(2,3-dichlorophenyl)-N’-benzoylthiourea 
• 6590-97-2 2,3-dichloro-1-isothiocyanatobenzene 

Downstream Products

• 107305-52-2 17β-[2-(2,3-dichloro-anilino)-thiazol-4-yl]-17α-hydroxy-androst-4-en-3-one 
• 69347-88-2 1-(2,3-Dichloro-phenyl)-2-methyl-isothiourea; hydriodide 
• 1030631-27-6 C₂₀H₁₄Cl₂N₄OS₂ 
• 1246779-98-5 BrH*C₁₇H₉Cl₃N₄OS 
• 1267448-26-9 6,7-dichloro-4-phenyl-2H-pyrimido[2,1-b]benzothiazol-2-one 
• 1849-71-4 4,5-dichloro-1,3-benzothiazol-2-amine 
• 929561-28-4 C₁₇H₁₄Cl₂N₂O₂S 
• 119155-39-4 N-(2,3-Dichloro-phenyl)-morpholine-4-carboxamidine; hydriodide 

Relevant academic research and scientific papers

Discovery of 6-[(3 S,4 S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor

Src homology 2 (SH2) domain-containing phosphatase 2 (SHP2) plays a role in receptor tyrosine kinase (RTK), neurofibromin-1 (NF-1), and Kirsten rat sarcoma virus (KRAS) mutant-driven cancers, as well as in RTK-mediated resistance, making the identification of small-molecule therapeutics that interfere with its function of high interest. Our quest to identify potent, orally bioavailable, and safe SHP2 inhibitors led to the discovery of a promising series of pyrazolopyrimidinones that displayed excellent potency but had a suboptimal in vivo pharmacokinetic (PK) profile. Hypothesis-driven scaffold optimization led us to a series of pyrazolopyrazines with excellent PK properties across species but a narrow human Ether-à-go-go-Related Gene (hERG) window. Subsequent optimization of properties led to the discovery of the pyrimidinone series, in which multiple members possessed excellent potency, optimal in vivo PK across species, and no off-target activities including no hERG liability up to 100 μM. Importantly, compound 30 (IACS-15414) potently suppressed the mitogen-activated protein kinase (MAPK) pathway signaling and tumor growth in RTK-activated and KRASmut xenograft models in vivo.

Synthesis and antitumor evaluation of 5-(benzo[: D] [1,3]dioxol-5-ylmethyl)-4-(tert -butyl)- N -arylthiazol-2-amines

A series of novel N-aryl-5-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(tert-butyl)thiazol-2-amines (C1-C31) were synthesized and evaluated for their antitumor activities against HeLa, A549 and MCF-7 cell lines. Some tested compounds showed potent growth inhibition properties with IC50 values generally below 5 μM against the three human cancer cells lines. Compound C27 showed potent activities against HeLa and A549 cell lines with IC50 values of 2.07 ± 0.88 μM and 3.52 ± 0.49 μM, respectively. Compound C7 (IC50 = 2.06 ± 0.09 μM) was the most active compound against A549 cell line, while compound C16 (IC50 = 2.55 ± 0.34 μM) showed the best inhibitory activity against the MCF-7 cell line. The preliminary mechanism of the inhibitory effect was investigated via further experiments, such as morphological analysis by dual AO/EB staining and Hoechst 33342 staining, and cell apoptosis and cycle assessment by FACS analysis. The results illustrated that compound C27 could induce apoptosis and cause both S-phase and G2/M-phase arrests in HeLa cell line. Therefore, compound C27 could be developed as a potential antitumor agent.

4′-Methyl-4,5′-bithiazole-based correctors of defective ΔF508-CFTR cellular processing

The synthesis and ΔF508-CFTR corrector activity of a 148-member methylbithiazole-based library are reported. Synthetic routes were devised and optimized to generate methylbithiazole analogs in four steps. Corrector potency and efficacy were assayed using epithelial cells expressing human ΔF508-CFTR. These structure-activity data establish that the bithiazole substructure plays a critical function; eight novel methylbithiazole correctors were identified with low micromolar potencies.

Improved Procedures for the Preparation of Cycloalkyl-, Arylalkyl-, and Arylthioureas

An improved procedure for the preparation of arylthioureas consists of the reaction of benzoyl isothiocyanate with anilines in acetone and debenzoylation of the resultant N-aryl-N'-benzoylthioureas with 5percent aqueous sodium hydroxide.Bicycloalkylthioureas and N-(arylalkyl)thioureas (e.g. 9H-9-fluorenylthiourea) are directly prepared from the corresponding isothiocyanates and ammonia.